a Department of Biochemistry, Faculty of Medicine , Medical University of Lodz , Lodz , Poland.
b Department of General and Colorectal Surgery, Faculty of Military Medicine , Medical University of Lodz , Lodz , Poland.
Expert Rev Clin Pharmacol. 2018 Jul;11(7):729-739. doi: 10.1080/17512433.2018.1494571. Epub 2018 Jul 9.
Irritable bowel syndrome (IBS) is a functional gut disorder that typically manifests in early adult years. One of the two major symptoms of the disease is chronic, visceral pain. The patients report pain as the most distressing symptom with the greatest impact on quality of life, challenging both to patients and healthcare providers. Areas covered: This review focuses on the pathophysiology of abdominal pain in IBS and describes current treatment possibilities. It also covers latest findings that may lead to novel pharmacological options in IBS pain management. Expert commentary: Pain is the main contributor to severity in IBS. Seeking pain alleviation is the most common reason that IBS sufferers consult with their physicians. Not all patients report being satisfied with available treatments for pain in IBS and there is a pressing need to find new, more efficient therapies for this syndrome.
肠易激综合征(IBS)是一种功能性肠道疾病,通常在成年早期出现。该疾病的两个主要症状之一是慢性内脏疼痛。患者报告疼痛是最令人痛苦的症状,对生活质量的影响最大,给患者和医疗保健提供者都带来了挑战。
本篇综述专注于 IBS 腹痛的病理生理学,并描述了当前的治疗可能性。它还涵盖了最新的发现,这些发现可能为 IBS 疼痛管理带来新的药理学选择。
疼痛是 IBS 严重程度的主要原因。寻求疼痛缓解是 IBS 患者向医生咨询的最常见原因。并非所有患者都报告对 IBS 疼痛的现有治疗方法感到满意,因此迫切需要为这种综合征找到新的、更有效的治疗方法。